AL
Alnylam
ALNY·NASDAQCambridge MAFounded 20022,600 employees
Large CapbiotechPublicRare DiseaseCardiologyCNS
Platform: RNAi/siRNA
Market Cap
$32B
All Drugs
8
Clinical Trials
11
Failed / Terminated
6
FDA Approved
1
Stock Price & Catalysts (ALNY)
Loading ALNY stock data...
Drug Pipeline (8 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| ALN-8757 | ALN-8757 | Preclinical | 1 | TIGIT | BCC | ||
| ALN-5628 | ALN-5628 | Phase 1/2 | 1 | APOC3 | Breast CaLN | ||
| ALN-3958 | ALN-3958 | Phase 2 | 1 | MALT1 | PNH | ||
| ALN-6288 | ALN-6288 | Approved | 1 | LAG-3 | DravetRB | ||
| ALN-3284 | ALN-3284 | Phase 2/3 | 1 | CDK2 | PTSDPV | ||
| Miriglumide | ALN-6059 | Phase 3 | 2 | CD3 | Pancreatic CaCervical Ca | ||
| Cevisacituzumab | ALN-9949 | Preclinical | 2 | MALT1 | RBMCL | ||
| Sovarelsin | ALN-4879 | Phase 2/3 | 2 | LAG-3 | MCLCSU |
SEC Filings & Financial Documents
Insider Trading Activity
Fetching insider trading data from SEC EDGAR...
Catalyst Events (11)